[Radiotherapy of esthesioneuroblastoma].
OBJECTIVE
To evaluate the radiocurability of esthesioneuroblastoma, we have retrospectively analyzed the results of radiation therapy in this tumor in our clinic.


METHODS
From 1985 through 1990, twelve patients with esthesioneuroblastoma have been treated at the Department of Radiotherapy at the University of Erlangen. Two had Kadish stage A, one stage B, and nine stage C. There were seven males and five females with a mean age of 43 years. Eleven patients had combined transcranial-transbasal surgery prior to radiotherapy (five R0-, four R1-, and two patients R2-resections) and one received radiotherapy only. The dose was 12 to 60 Gy (mean 54 Gy) in 1.8 Gy to 2 Gy per fraction.


RESULTS
8/12 patients (67%) were locally controlled. One had progressive disease during radiotherapy after partial resection and died. Three had local recurrences, one in-field and two marginal. One patient with a local recurrence developed cervical lymph node metastases, and one locally controlled patient developed bone metastases but is alive eight years after chemotherapy plus radiotherapy for metastatic disease. The five-year-overall and recurrence-free survival was 72% and 55%, respectively.


CONCLUSIONS
Sophisticated surgery plus radiotherapy may cure a reasonable number of patients with esthesioneuroblastoma.
Strnad
V
V
Strahlentherapeutische Klinik und Poliklinik, Universität Erlangen-Nürnberg.
Grabenbauer
G G
GG
Dunst
J
J
Sauer
R
R
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery; D012189:Retrospective Studies
Radiotherapie beim Asthesioneuroblastom.